Novartis announced full year 2025 results on February 4, 2026, showing net sales growth of 8% and core operating income up 14%. Core operating margin reached 40.1%, and core EPS grew 17% to USD 8.98. Priority brands including Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx showed strong performance. The company approved a dividend increase of 5.7% to CHF 3.70 per share. However, 2026 guidance indicated net sales expected to grow low single-digit and core operating income expected to decline low single-digit. Additionally, on February 25, 2026, Novartis announced plans for a new radioligand therapy manufacturing site in Denton, Texas, expected to be operational in 2028. The modest stock decline of 0.1% may reflect the cautious 2026 outlook despite strong 2025 performance.
Novartis announced full year 2025 results on February 4, 2026, showing net sales growth of 8% and core operating income up 14%. Core operating margin reached 40.1%, and core EPS grew 17% to USD 8.98. Priority brands including Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx showed strong performance. The company approved a dividend increase of 5.7% to CHF 3.70 per share. However, 2026 guidance indicated net sales expected to grow low single-digit and core operating income expected to decline low single-digit. Additionally, on February 25, 2026, Novartis announced plans for a new radioligand therapy manufacturing site in Denton, Texas, expected to be operational in 2028. The modest stock decline of 0.1% may reflect the cautious 2026 outlook despite strong 2025 performance.
Novartis is a Swiss pharmaceutical giant with a portfolio spanning oncology, immunology, cardiovascular, and radioligand therapies, anchored by growth drivers Kisqali, Kesimpta, Pluvicto, and Scemblix that collectively drove 8% sales growth in 2025. The company reported Q4 results in early February showing 40% core margins and guided for low single-digit sales growth in 2026 as it navigates its largest-ever patent expiry cycle. Today's announcement of a fifth US radioligand therapy manufacturing site in Texas underscores its commitment to expanding domestic production capacity for its fast-growing Pluvicto franchise.